Last reviewed · How we verify

Heparin Low Dose

University Hospital, Bordeaux · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Heparin Low Dose is a Small molecule drug developed by University Hospital, Bordeaux. It is currently FDA-approved.

Heparin Low Dose is used to treat conditions such as Pulmonary Thromboembolisms, Pulmonary Embolism, Anemia, Sickle Cell, and Acute Chest Syndrome. It works as an Antithrombin-III activator, a type of oligosaccharide that belongs to the ACTIVATOR drug class.

At a glance

Generic nameHeparin Low Dose
SponsorUniversity Hospital, Bordeaux
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Heparin Low Dose

What is Heparin Low Dose?

Heparin Low Dose is a Small molecule drug developed by University Hospital, Bordeaux.

Who makes Heparin Low Dose?

Heparin Low Dose is developed and marketed by University Hospital, Bordeaux (see full University Hospital, Bordeaux pipeline at /company/university-hospital-bordeaux).

What development phase is Heparin Low Dose in?

Heparin Low Dose is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing